"While the Food and Drug Administration decision on new drugs usually follows the recommendations of the advisory committee..."; this oft used proviso is used to either indicate a pending FDA decision or an FDA decision that is contrary to the recommendation of the advisory committee co
Subtle early bony changes in inflammatory arthritis can be hard even for experienced rheumatologists to interpret, even though they have traditionally been considered to become disease-defining as they progress.
EULAR 2021 opened with a grand debate to answer this essential question: should clinicians treat to remission or to Lupus Low Disease Activity State (LLDAS)?
Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.
An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351).
Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response.
Cutaneous lupus erythematosus (CLE) consists of a wide range of dermatologic manifestations seen in people with or without systemic lupus erythematosus (SLE). CLE can be categorised into LE-specific lesions, i.e.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
